Leishmaniasis includes a spectrum of diseases ranging from debilitating cutaneous to fatal
visceral infections. This disease is caused by the parasitic protozoa of the genus Leishmania …

Cytokines play crucial roles in commencing and coordinating the organized recruitment and
activation of immune cells during infection. These molecular regulators play an important …

Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL),
a potentially fatal disease caused by infection with Leishmania parasites. In the current …

Visceral leishmaniasis (VL) is a debilitating human pathogenesis in which the body's
immune functions are severely compromised. Various subsets of T cells, including Th17 …

The control measures against visceral leishmaniasis (VL) include a precise diagnosis of
disease, the treatment of human cases, and reservoir and vector controls. However, these …

Abstract Treatment against visceral leishmaniasis (VL) presents problems by the toxicity of
drugs, high cost and/or emergence of resistant strains. The diagnosis is hampered by …

Skin lesions in nonulcerated cutaneous leishmaniasis (NUCL) caused by Leishmania (L.)
infantum chagasi are characterized by a mononuclear inflammatory infiltrate in the dermis …

Visceral leishmaniasis (VL) is a serious neglected tropical disease that affects humans and
dogs in urban areas. There are no vaccines against human VL, and few licensed canine VL …

Vaccination against visceral leishmaniasis (VL) should be considered as a safe and
effective measure to disease control; however, few vaccines are available against canine VL …

Objective: To evaluate the immunostimulatory potential of cross-reactive molecule heat
shock protein 60 (HSP60) of filarial parasite Brugia malayi and Leishmania donovani …